The Ron receptor tyrosine kinase (macrophage stimulating 1 receptor) is overexpressed in approximately 50% of human breast cancers. Transgenic mice overexpressing Ron in the mammary epithelium [mouse mammary tumor virus driven (MMTV)-Ron expressing mice] develop mammary tumors that exhibit up-regulation of ␤-catenin and ␤-catenin target genes. ␤-Catenin has been shown to be a mediator of mammary tumorigenesis in various breast cancer models, including downstream of Ron. However, the in vivo impact of a conditional loss of ␤-catenin downstream of Ron receptor overexpression on the onset, growth, turnover, and metastasis of mammary tumors has not been addressed. To determine the significance of ␤-catenin in the context of Ron overexpression, we conditionally deleted ␤-catenin in mammary epithelial cells of MMTV-Ron mice. Conditional deletion of ␤-catenin in the mammary epithelium, through the use of whey acidic protein (WAP)-Cre transgenic mice, significantly delayed the onset of mammary hyperplastic nodules, the presence of palpable mammary tumors, and ultimately decreased liver metastasis. ␤-Catenin loss in this model was also associated with decreased expression of cyclin D1. In total, these studies support an important role for ␤-catenin downstream of Ron receptor signaling during the development of mammary tumorigenesis. (Endocrinology 153: 2735-2746, 2012) 
B
reast cancer is the second leading cause of cancer death among women in the United States (American Cancer Society, 2009 -2010) . Standard treatment options for breast cancer include radiation therapy, chemotherapy, hormone therapy, and/or targeted therapy. Although the use of specific monoclonal antibodies and tyrosine kinase inhibitors in combination with chemotherapy has shown promise in clinical studies, breast tumor recurrence and the lack of continued disease-free survival persist (1, 2) . Therefore, the identification of new biomarkers and drug targets remains a high priority.
The Ron receptor tyrosine kinase, also referred to as macrophage stimulating 1 receptor (Mst1R), is up-regulated in about half of human breast cancers (3, 4) . In addition to breast cancer, Ron overexpression is also seen in several human epithelial cancers, including lung, stomach, colon, pancreas, and prostate cancers (2, (5) (6) (7) . Overexpression of Ron has been shown to induce proliferation and migration of cells in vitro and tumor formation in vivo (2, 8, 9) . Recently, expression of Ron, hepatocyte growth factor-like protein (HGFL) (the Ron ligand), and matriptase, a serine protease that cleaves pro-HGFL, were associated with poor overall survival among patients without metastatic disease at the time of primary tumor resection (10) . Ron activation by HGFL has been shown to trigger activation of a number of signaling cascades, including phosphatidylinositol 3-kinase/Akt, MAPK, c-Jun NH 2 -terminal kinase, and ␤-catenin, which affect cell proliferation, differentiation, and migration (6, 7, (11) (12) (13) .
We have previously shown that overexpression of Ron in the mouse mammary epithelium induces tumor formation in 100% of female mice and is associated with elevated levels of ␤-catenin and the up-regulation of ␤-catenin target genes, including cyclin D1 and c-myc (9) . Increased ␤-catenin, localized to the nuclear and cytoplasmic compartments, is observed in about 40% of primary breast tumors and is associated with poor prognosis and poor patient survival (14) . Dysregulated ␤-catenin signaling leads to perturbation of mammary stem and progenitor cell dynamics as well as mammary tumor formation in mice (15) (16) (17) (18) . The Ron receptor is also an important regulator of pubertal mouse mammary gland development, because mice with a targeted deletion of the Ron tyrosine kinase domain exhibit alterations in mammary ductal extension and branching morphogenesis (19) .
Based on these reports, we hypothesized that ␤-catenin is important for Ron-induced mammary tumor initiation, progression, and metastatic disease in vivo. Here, we show that decreasing the expression of ␤-catenin within the mammary epithelium of transgenic mice overexpressing Ron induces a delay in palpable mammary tumor development compared with control mice. These differences were associated with a delay in the onset of mammary hyperplasia and the down-regulation of the ␤-catenin target gene cyclin D1. Our findings demonstrate and further support an important link between the Ron receptor and its downstream signaling mediator, ␤-catenin, in regulating mammary gland tumorigenesis in vivo.
Materials and Methods

Generation of mice
Mice with mammary-specific Ron overexpression, referred to as mouse mammary tumor virus driven (MMTV)-Ron mice, and mice with a floxed ␤-catenin allele (␤-cat F/F ) were previously described (9, 20) . These two mouse lines were crossed to produce mice overexpressing Ron in the mammary gland and having ␤-catenin floxed (MMTV-Ron ␤-cat F/F ). ␤-Catenin deletion in the mammary glands of MMTV-Ron ␤-cat F/F mice was achieved by crossing MMTV-Ron ␤-cat F/F mice to mice that expressed the whey acidic protein (WAP)-Cre transgene (21) . Our study groups consisted of MMTV-Ron ␤-cat F/F (control) and MMTVRon ␤-cat F/F WAP-Cre mice. Genotyping of the transgenic mice was performed by PCR analysis with the following temperature conditions: annealing, 59 C and elongation, 72 C; and primer sets: ␤-catenin primers forward, 5Ј-ACT GCC TTT GTT CTC TTC CCT TCT G-3Ј and reverse, 5Ј-CAG CCA AGG AGA GCA GGT GAG G-3Ј and WAP-Cre forward, 5Ј-CAT CAC TCG TTG CAT CGA CC-3Ј and reverse 5Ј-TAG AGC TGT GCC AGC CTC TTC-3Ј. All animal procedures were approved by the University of Cincinnati Institutional Animal Care and Use Committee.
Tumor latency
To accelerate mammary tumorigenesis in our MMTV-Ron model and to offer the most frequent expression of WAP-Cre and ultimately ␤-catenin deletion, our study animals were maintained as continuous breeding pairs, starting at 8 wk of age until palpable tumor development. Female MMTV-Ron transgenic mice are unable to nurse their offspring to weaning. Therefore, all pups were removed within 1-2 d after parturition from the transgenic dams and breeding continued. Two weeks before a scheduled harvest date, all study animals were isolated and monitored to ensure that dams were not pregnant. If any dams appeared pregnant, they were then scheduled for a later time point. After parturition, pups were removed (if applicable), and dams underwent a minimal 10-d involution period before mammary gland and tissue harvest. Animals were palpated weekly for over 400 d, and palpable tumor incidence was plotted against time. Tumor development in MMTV-Ron ␤-cat F/F and MMTV-Ron ␤-cat F/F WAP-Cre mice were subjected to Kaplan-Meier analysis using GraphPad Prism (GraphPad Software, San Diego, CA) as previously described (9, 11) . All mice were injected with bromodeoxuridine (BrdU) 2 h before being euthanized by CO 2 asphyxiation, and mammary glands, mammary tumors, liver, and lungs were removed, frozen, or processed for histological examination.
Tissue histology and immunohistochemistry
Thoracic mammary glands were snap frozen for RNA and protein isolation. Any palpable tumor within the thoracic gland was excised, cut into 5-mm slices, and processed for RNA and protein separately from the normal/hyperplastic mammary glands. Inguinal mammary glands were used for whole-mount analysis and histological assessment. Formalin-fixed mammary glands were embedded in paraffin, sectioned at 5 m, and stained with hematoxylin and eosin Y for routine histological assessment. To detect ␤-catenin, formalin-fixed paraffin-embedded sections were incubated in citrate buffer for antigen retrieval as recommended by the manufacturer. After rinsing in PBS, slides were incubated overnight with a polyclonal rabbit antibody directed against ␤-catenin (RB-9035; Neomarkers, Fremont, CA). ␤-Catenin was visualized using a biotinylated-conjugated antirabbit secondary antibody and the ABC technique (Vector Laboratories, Burlingame, CA) followed by diaminobenzidine (Sigma, St. Louis, MO). Slides were counterstained with Harris modified hematoxylin (Harris modified; Fisher Scientific, Pittsburgh, PA). A minimum of three animals was assessed per genotype.
Mitotic and cell death indices were assessed in normal ductal epithelium, hyperplastic nodules, and tumors by quantitative morphometric analysis of BrdU incorporation and in situ terminal transferase-mediated 2Ј-deoxyuridine, 5Ј-triphosphate nick end labeling (TUNEL). For the mitotic index, mice were injected with BrdU 2 h before harvest, and BrdU was localized in sections with a mouse monoclonal biotinylated anti-BrdU antibody (Zymed Laboratories, Inc., San Francisco, CA), and the ABC technique followed by diaminobenzidine. DNA fragmentation was assessed by TUNEL assay using a commercially available kit (Millipore, Billerica, MA) after optimization of pretreatment conditions and reagent dilutions to ensure that labeling was restricted to cells with apoptotic morphology. For both assays, tissues were counterstained with hematoxylin.
BrdU incorporation and TUNEL were quantified in normal ductal epithelium, hyperplastic nodules, and tumors within tissue sections viewed and photographed at ϫ400 magnification. A minimum of three animals was assessed per genotype, with three to six fields per section and a minimum of 300 epithelial cells assessed per slide. The photographs were analyzed, and the percentage of epithelial cells that labeled positive for BrdU or TUNEL was calculated.
For whole-mount analysis, mammary glands were fixed in Carnoy's fixative and stained overnight in carmine alum. Samples were dehydrated, cleared in xylene, mounted, and examined on a stereoscope equipped with an Axiovert digital camera.
Quantitative real-time (qRT)-PCR
Total RNA was isolated from tissues using TRIzol reagent (Invitrogen, Carlsbad, CA). qRT-PCR was performed using an ABI7900HT (Applied Biosystems by Life Technologies, Carlsbad, CA) as previously described (19, 22) . Briefly, independent mammary gland or tumor RNA preparations from six mice of each genotype were made at the time points indicated. Total RNA was reverse transcribed using the High Capacity kit (Applied Biosystems), and a cDNA stock was generated from each RNA sample. Each cDNA was independently analyzed in duplicate (60 ng of cDNA/well) using specific primer sets that were designed with Primer Express 3.0 software (Applied Biosystems). The primers used the default annealing/elongation temperature (60 C), and a SYBR green (Roche Diagnostics, Indianapolis, IN) dissociation curve was performed for each primer set to ensure that a single gene product was being amplified with each primer set. The resulting primer sets were: ␤-catenin forward, 5Ј-TCCCTGAGACGCTAGATGAGG-3Ј and reverse, 5Ј-CGTTTAGCAGTTTTGTCAGCTC-3Ј and cyclin D1 forward, 5Ј-GCGTACCCTGACACCAATCTC-3Ј and reverse, 5Ј-CTCCTCTTCGCACTTCTGCTC-3Ј. Gene expression values were normalized to ␤-glucuronidase mRNA: forward, 5Ј-TTGAGAACTGGTATAAGACGCATCAG-3Ј and reverse, 5Ј-TCTGGTACTCCTCACTGAACATGC-3Ј as an internal control and are reported as normalized gene expression. For data presentation, duplicate values from each run were averaged, and the six values were then averaged to generate one value for each genotype/time point. The level of expression was determined using a standard curve (log range Ϫ10 4 ) dilution series method comparison. The final data are expressed as the mean Ϯ SE of six animals per time point.
Western blot analysis
Protein was isolated from tissues as described previously (9) . Proteins were separated by SDS-PAGE and transferred to Immobilon-P membranes (Millipore). After transfer, the membranes were probed with a rabbit monoclonal anti-␤-catenin antibody (1:1000; Cell Signaling, Danvers, MA). The membranes were stripped and reprobed with a mouse monoclonal anticyclin D1 antibody (1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Actin or tubulin expression was used as the loading control. A minimum of three animals was assessed per genotype per time point with multiple assessments analyzed per mammary gland.
Statistical analysis
Statistical analysis for the detection of hyperplastic nodules was determined using the 2 test. Statistical significance for BrdU incorporation, TUNEL analysis, qRT-PCR, and tumor metastasis was determined by the Student's t test using GraphPad Prism software. Data on hyperplastic nodules and tumor development were subjected to Kaplan-Meier analysis using GraphPad Prism software. Means were considered significantly different if a P value of less than 0.05 was obtained.
Results
␤-Catenin expression in MMTV-Ron ␤-cat F/F WAPCre mice during involution
To determine the impact of altering ␤-catenin expression within the mammary epithelium during Ron-induced mammary tumorigenesis, we used the MMTV-Ron transgenic mice that were shown previously to develop aggressive and highly metastatic breast cancer as a result of Ron receptor overexpression in the mammary epithelium (9) . We crossed the MMTV-Ron mice with mice containing a (Fig. 1C) . To accelerate mammary tumorigenesis in our MMTV-Ron model and to offer the most frequent expression of WAP-Cre and ultimately ␤-catenin deletion, our study animals were maintained as continuous breeding pairs to optimize transgene promoter expression, and newly born pups were removed within 48 h after parturition.
Deletion of ␤-catenin delays the onset of mammary hyperplasia in MMTV-Ron mice
To define the impact that deletion of ␤-catenin has on the incidence, the initiation of hyperplastic nodules, and the presence of palpable mammary tumors in MMTVRon mice, we isolated mammary glands at 2.5, 4, 6, 8, and 10 months of age from MMTV-Ron ␤-cat F/F (control) and MMTV-Ron ␤-cat F/F WAP-Cre mice. Female mice were housed with male mice up until 2 wk before their scheduled harvest date. If any dams appeared pregnant, then they were scheduled for a later time point, allowing for at least a 10-d involution period before mammary gland harvest. Inguinal mammary glands were examined by wholemount and histological analysis for the presence of hyperplastic nodules. Hyperplastic nodules were determined by the presence of a congregated cell mass around the ducts of the mammary gland. Hyperplastic areas were identified in control MMTV-Ron ␤-cat F/F mammary glands as early as 2.5 months of age with the majority of animals exhibiting mammary hyperplasia by 4 months of age ( Fig. 2A) . In contrast, no hyperplasia was evident in MMTV-Ron ␤-cat F/F WAP-Cre glands at 2.5 months and only sparsely detectable by 4 months of age (Fig. 2B) 2B ) mice had a delay in the onset of mammary gland hyperplastic nodules compared with control mice at every time point examined with statistical differences observed between groups at 4 months of age. The delay in the onset of mammary gland hyperplasia in the MMTV-Ron ␤-cat F/F WAP-Cre mouse model is depicted using a Kaplan-Meier graph with mammary hyperplastic nodules as the end point (Fig. 2C) . Thus, the onset of Ron-induced mammary tumorigenesis is delayed in the presence of WAP-Cre expression and a reduction in ␤-catenin expression.
WAP-Cre-induced deletion of ␤-catenin delays palpable mammary tumor development in MMTVRon mice
Palpable mammary tumor kinetics as a result of ␤-catenin loss by WAP-induced expression of Cre is depicted in Fig. 3A . Although mammary tumors form in 100% of the mice from both groups, palpable tumor development was significantly delayed in the MMTV-Ron ␤-cat (Fig. 4, A and B) . At this early time point, there were no changes in cyclin D1 protein or RNA levels. Immunohistochemical detection of ␤-catenin expression and localization was also performed on MMTV-Ron ␤-cat
and MMTV-Ron ␤-cat F/F WAP-Cre glands (Fig. 4C) , which also showed a decrease in ␤-catenin expression in glands from the MMTV-Ron ␤-cat F/F WAP-Cre compared with glands from the control mice. At this early time point, there were no differences observed in the percentage of cells staining positive for BrdU incorporation. Interestingly, however, there was a decrease in the number of TUNEL staining mammary epithelial cells between genotypes with MMTV-Ron ␤-cat F/F WAP-Cre glands exhibiting less cell death (Fig. 4, D and E) . These results show efficient ␤-catenin deletion in the mammary epithelium at 4 months of age, a time point when hyperplastic nodules are less prevalent in the MMTV-Ron ␤-cat F/F WAP-Cre glands.
Reduced ␤-catenin expression in mammary glands from MMTV-Ron ␤-cat F/F WAP-Cre mice at 8 months
Hyperplastic nodules were present in a majority of the mammary glands assessed from MMTV-Ron ␤-cat F/F and MMTV-Ron ␤-cat F/F WAP-Cre mice by 8 months of age. To determine the extent of ␤-catenin deletion at this time point, thoracic mammary glands from MMTV-Ron ␤-cat F/F and MMTV-Ron ␤-cat F/F WAP-Cre mice were used to isolate RNA and protein to examine ␤-catenin and cyclin D1 expression by qRT-PCR (Fig. 5A) and Western blot analysis (Fig. 5B) . ␤-Catenin expression was also examined by immunohistochemistry (Fig. 5C) . A significant reduction in ␤-catenin mRNA and protein expression was observed in MMTV-Ron ␤-cat F/F WAP-Cre glands compared with controls, which also corresponded with a slight reduction in cyclin D1 mRNA and protein expression, although this latter trend was not significant. In addition, MMTV-Ron ␤-cat F/F WAP-Cre mammary glands had significantly reduced numbers of epithelial cells undergoing proliferation, as indicated by a lower percentage of cells having BrdU incorporation. The glands from MMTVRon ␤-cat F/F WAP-Cre mice also had a reduction in the number of cells undergoing apoptosis, quantified by TUNEL staining in comparison with control glands at this time point (Fig. 5, D and E) . These results suggest that the early and continued conditional loss of ␤-catenin at 8 months of age is associated with reduced mammary cell proliferation, albeit with a consistent decrease in cell death, which is also associated with decreased palpable tumor formation as depicted in Fig. 3A . Decreased metastatic burden to the liver in MMTV-Ron mammary tumors with ␤-catenin deleted Serial sections of the lung and liver from control MMTV-Ron ␤-cat F/F and MMTV-Ron ␤-cat F/F WAP-Cre mice were examined histologically for the presence of mammary tumor metastasis. A high frequency of metastasis to the lungs and liver was observed in both groups (Table 1) . Interestingly, the incidence of liver metastasis in MMTV-Ron ␤-cat F/F WAP-Cre mice was significantly reduced compared with that observed in the MMTV-Ron ␤-cat F/F control mice. Figure 7 shows representative images of lung and liver metastases from control MMTV-Ron ␤-cat F/F and MMTV-Ron ␤-cat F/F WAP-Cre mice.
␤-Catenin
Discussion
We have previously shown that Ron overexpression in the mammary epithelium results in mammary tumors in 100% of MMTV-Ron transgenic mice, and these tumors are associated with elevated ␤-catenin expression (9) . In this study, we examined the effect of a conditional deletion of ␤-catenin in the context of Ron overexpression within the mammary gland to assess the impact ␤-catenin deletion has on the development and progression of Ron-induced mammary tumorigenesis. Here, we show that the development of mammary hyperplasia is delayed in MMTV-Ron mice when ␤-catenin is deleted through the use of WAP-Cre transgenic mice. The onset of palpable mammary tumor formation in MMTV-Ron ␤-cat F/F WAP-Cre mice was also significantly delayed compared with the control mice with a median tumor latency of 312 d in the MMTV-Ron ␤-cat F/F WAP-Cre mice compared with 283 d in the control mice.
The delay in mammary tumorigenesis is consistent with our data showing a decrease in the proliferation rate of the MMTV-Ron ␤-cat F/F WAP-Cre hyperplastic nodules, corresponding with the loss or reduction in ␤-catenin and cyclin D1 expression in the mammary tumors of the MMTV-Ron ␤-cat F/F WAP-Cre mice compared with controls. Additionally, we showed a decrease in cell death based on TUNEL staining in the mammary glands of MMTV-Ron ␤-cat F/F WAP-Cre mice compared with MMTV-Ron ␤-cat F/F mice in hyperplastic nodules. We speculate that the reduced number of TUNEL positive epithelial cells in the MMTV-Ron ␤-cat F/F WAP-Cre mice may coincide with the proportion of cells that express ␤-catenin, although further investigation into this difference is needed. Together, our studies support the supposition that conditional loss of ␤-catenin has an important effect on our model system, particularly during early stages of Ron-induced tumorigenesis. Along these lines, at 4 months of age, there were no noted differences between genotypes in the percentage of tumor-free mice over time with neither genotype exhibiting palpable tumors at this stage. However, there was a significant increase in the percentage of glands from MMTV-Ron ␤-cat F/F mice that contained hyperplastic nodules compared with the MMTVRon ␤-cat F/F WAP-Cre mice. In contrast, by 8 months of age, conditional loss of ␤-catenin results in a significant difference in the number of mice with palpable mammary tumors as well as a reduction in mammary gland proliferation when compared with MMTVRon ␤-cat F/F mice. After about 10 months of age through end-stage tumor analysis, ␤-catenin and cyclin D1 expression levels were reduced in the MMTV-Ron ␤-cat F/F WAP-Cre compared with controls, but the tumor proliferation and apoptotic rates became more similar in the end-stage samples. Thus, these results suggest that ␤-catenin may play an important role during early tumor development, after which there may be limited further consequences of ␤-catenin loss.
Despite the importance of the conditional loss of ␤-catenin in the development of hyperplastic nodules and palpable mammary tumors, the late stage mammary tumors did not differ in proliferation rates between genotypes even with a reduction in ␤-catenin and a decrease in cyclin D1 expression in the MMTV-Ron ␤-cat F/F WAP-Cre mice. The apparent paradox in the low levels of cyclin D1 without a change in proliferation in our late stage tumors is similar to previous reports, which have shown no significant differences in proliferative activity between high and low cyclin D1 expressing tumors in human papillary superficial bladder cancers (23) . Further, both cyclin D1 and Ki67 (a proliferation marker) were shown to be independent predictors of reduced disease-free survival with patients having low cyclin D1, low p27 kip1 , and high Ki67 expression defining a "high-risk" group of patient with an increased risk of disease recurrence. Others have also suggested that a determining factor for cell proliferation may be the balance between regulators of cell proliferation including p27 kip1 and cyclin D/cdk4 levels (24) .
In addition to differences in the onset of hyperplasia and palpable tumor formation, we also report a delay in mammary tumor cells metastasizing to the liver in the MMTV-Ron ␤-cat F/F WAP-Cre mice compared with the rate of metastasis in our control mice. Contrary to the liver metastasis, metastasis to the lung was not different be- tween the two groups. However, because lung metastasis was only assessed at the end-stage time point and both genotypes had greater than 90% of the mice with metastatic burden to the lung at this time, it remains unknown whether lung metastasis may have differed between the MMTV-Ron ␤-cat F/F WAP-Cre and control mice at an earlier time point. Lung metastasis may have occurred as an earlier event in the MMTV-Ron-induced mammary tumor model compared with liver metastases, or these data could also suggest that ␤-catenin expression may be important in the establishment or growth of liver metastases. In total, these studies suggest that continued suppression of ␤-catenin within the mammary epithelium results in a delay in mammary tumor onset and decreased overall metastatic tumor burden.
Deregulation of ␤-catenin signaling within luminal progenitor cells has been found to produce tumors of mixed lineage (17, 25) . Histologically, MMTV-Ron ␤-cat F/F WAP-Cre mammary tumors were also highly associated with foci of central keratinization found within concentric layers of abnormal squamous cells. Breast cancer from patients and mice with alterations in BRCA1 frequently exhibit basal-like phenotypes, which contain metaplastic elements consisting of neoplastic spindle cells or squamous cells with the presence of keratin pearls (26 -28) . These similarities suggest that mammary tumors from the MMTV-Ron ␤-cat F/F WAP-Cre mice may have attributes of a murine model of basal-like breast cancer, although further investigation into these tumors is warranted to determine whether this model may prove useful for examining new treatment modalities that target BRCA1-driven and/or basal-like carcinomas.
Although the tumors in both the MMTV-Ron ␤-cat F/F and MMTV-Ron ␤-cat F/F WAP-Cre mice were very aggressive, the disparate tumor phenotypes in the MMTV-Ron ␤-cat F/F and MMTV-Ron ␤-cat F/F WAP-Cre models may be due to a combination of factors. Although efficient ␤-catenin loss was observed in MMTV-Ron ␤-cat F/F WAPCre mammary tumors compared with those from MMTV-Ron ␤-cat F/F mice, it is important to note that the pattern of ␤-catenin deletion was mosaic. This point is important, because ␤-catenin has been shown to play pivotal roles in the mammary gland regulating stem cell self renewal and multipotency, as well as promoting proliferation and cell survival during various stages of mammary gland development (17, 29, 30) . Further studies are needed to determine whether the phenotypes observed reflect ␤-catenin loss in different mammary epithelial cell types, the precise timing of this loss, and/or the extent of deletion of this protein during MMTV-Ron-induced tumorigenesis.
Overall, our data support previous studies demonstrating that Ron overexpression leads to the development of highly aggressive, metastatic mammary tumors (4, 9) . More specifically, previous work showed that Ron overexpression in the mammary epithelium of mice lead to mammary tumors that exhibited increases in ␤-catenin expression, activation, and tyrosine phosphorylation. Recently published studies have further identified an important role of the Ron receptor tyrosine kinase, and the Ron ligand HGFL, in the activation of ␤-catenin in breast cancer cells through tyrosine phosphorylation of tyrosine residues 654 and 670 in ␤-catenin (4). In this report, the WAP-Cre transgenic model provided a process by which we could investigate the consequences of a conditional loss of ␤-catenin within the in vivo mammary gland after glandular development had completed. In this experimental system, the extent of ␤-catenin loss was mosaic but provided important evidence that ␤-catenin loss in vivo during mammary tumor formation leads to a delay in the development of hyperplastic nodules and palpable mammary tumors. In our previous studies, using mammary tumor cell lines with a complete elimination of ␤-catenin, we demonstrated that complete loss of this protein in Ron- overexpressing mammary tumor cell lines was able to inhibit tumor cell growth both in vitro and using an orthotopic xenograph model (4) . These combined studies support an important role for ␤-catenin downstream of Ron receptor signaling during mammary tumorigenesis.
In an examination of human breast cancer specimens, a statistically significant correlation between high Ron expression and high ␤-catenin expression was observed (4) . Breast cancer patients with high Ron and high ␤-catenin expression exhibited significantly reduced survival within a 30-month follow-up period and more lymph node metastasis compared with patients with low Ron and ␤-catenin expression. In this report, we show that tumor formation in MMTV-Ron mice is regulated by ␤-catenin in vivo, wherein reduced ␤-catenin expression leads to increases in tumor latency, decreases in tumor growth, and a reduction in the metastatic burden to the liver. The extent and timing of ␤-catenin expression may play an important role in tumor growth, may regulate aspects of tumor histology, and may possibly alter ensuing responses to breast cancer treatment. Further understanding of the complex spatiotemporal expression of ␤-catenin will be required to provide insights into the development and eventual treatment of patients that exhibit activation of this pathway in breast cancer.
